CN109562098B - 用于立即治疗膜翅目注毒和其他因组胺释放引起的病症的pla2抑制剂 - Google Patents

用于立即治疗膜翅目注毒和其他因组胺释放引起的病症的pla2抑制剂 Download PDF

Info

Publication number
CN109562098B
CN109562098B CN201780040801.2A CN201780040801A CN109562098B CN 109562098 B CN109562098 B CN 109562098B CN 201780040801 A CN201780040801 A CN 201780040801A CN 109562098 B CN109562098 B CN 109562098B
Authority
CN
China
Prior art keywords
pla2
injection
varespladib
inhibitor
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780040801.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN109562098A (zh
Inventor
马修·R·勒温
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ophirex Inc
Original Assignee
Ophirex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ophirex Inc filed Critical Ophirex Inc
Priority to CN202310330976.4A priority Critical patent/CN116585306B/zh
Publication of CN109562098A publication Critical patent/CN109562098A/zh
Application granted granted Critical
Publication of CN109562098B publication Critical patent/CN109562098B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN201780040801.2A 2016-04-29 2017-05-01 用于立即治疗膜翅目注毒和其他因组胺释放引起的病症的pla2抑制剂 Active CN109562098B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310330976.4A CN116585306B (zh) 2016-04-29 2017-05-01 用于立即治疗膜翅目注毒和其他因组胺释放引起的病症的pla2抑制剂

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662329611P 2016-04-29 2016-04-29
US62/329,611 2016-04-29
US201662340075P 2016-05-23 2016-05-23
US62/340,075 2016-05-23
US201662423693P 2016-11-17 2016-11-17
US62/423,693 2016-11-17
PCT/US2017/030436 WO2017190141A1 (en) 2016-04-29 2017-05-01 Pla2 and hmg-coa inhibitors for treatment of pathological conditions causing hemolysis, cerebral edema, and acute kidney injury

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310330976.4A Division CN116585306B (zh) 2016-04-29 2017-05-01 用于立即治疗膜翅目注毒和其他因组胺释放引起的病症的pla2抑制剂

Publications (2)

Publication Number Publication Date
CN109562098A CN109562098A (zh) 2019-04-02
CN109562098B true CN109562098B (zh) 2023-04-21

Family

ID=60161200

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780040801.2A Active CN109562098B (zh) 2016-04-29 2017-05-01 用于立即治疗膜翅目注毒和其他因组胺释放引起的病症的pla2抑制剂
CN202310330976.4A Active CN116585306B (zh) 2016-04-29 2017-05-01 用于立即治疗膜翅目注毒和其他因组胺释放引起的病症的pla2抑制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202310330976.4A Active CN116585306B (zh) 2016-04-29 2017-05-01 用于立即治疗膜翅目注毒和其他因组胺释放引起的病症的pla2抑制剂

Country Status (9)

Country Link
US (2) US12383531B2 (enExample)
EP (1) EP3448378B1 (enExample)
JP (2) JP7542935B2 (enExample)
KR (2) KR102723249B1 (enExample)
CN (2) CN109562098B (enExample)
AU (2) AU2017257185B8 (enExample)
IL (2) IL262620B2 (enExample)
MX (2) MX391165B (enExample)
WO (1) WO2017190141A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3448378B1 (en) 2016-04-29 2024-04-17 Ophirex, Inc. Pla2 and hmg-coa inhibitors for treatment of pathological conditions causing hemolysis, cerebral edema, and acute kidney injury
US20240382452A1 (en) * 2021-11-09 2024-11-21 Ophirex, Inc. Compositions and dosage forms for topical and transdermal delivery of actives and methods of use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999029726A1 (en) * 1997-12-05 1999-06-17 Hsc (Pla) Pty. Ltd. Phospholipase inhibitor

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL84252A (en) 1987-10-23 1994-02-27 Yissum Res Dev Co Phospholipase inhibiting compositions
IL113210A (en) * 1994-04-01 2001-01-28 Lilly Co Eli 1H-indole-3- glyoxylamide spla2 inhibitors and pharmaceutical compositions containing them
RU2170232C2 (ru) * 1996-08-28 2001-07-10 Дзе Проктер Энд Гэмбл Компани Амиды фосфиновых кислот и способ предупреждения или лечения заболевания, связанного с нежелательной активностью металлопротеазы
GB2365769A (en) 2000-08-18 2002-02-27 Secr Defence Skin preparations containing silicon
US8106019B2 (en) * 2002-11-15 2012-01-31 Philadelphia Health & Education Corporation CHEC-7 a novel sPLA2 inhibitor
CA2538159A1 (en) 2003-09-09 2005-03-17 University Of Florida Research Foundation, Inc. Polyamine-metal chelator conjugates
FR2873293B1 (fr) * 2004-07-21 2006-11-17 Cerep Sa Utilisation d'un acide gras pour la preparation d'une composition topique destinee a l'apaisement des reactions inflammatoires dues aux piqures d'hymenopteres a venin
US20090234011A1 (en) * 2005-04-21 2009-09-17 Goldstein Glenn A N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress
CA2749534A1 (en) 2009-01-08 2010-07-15 Anthera Pharmaceuticals, Inc. Secretory phospholipase a2 (spla2) inhibitor and niacin drug compositions and methods for treating cardiovascular disease and dyslipidemia
US20110269786A1 (en) 2010-04-30 2011-11-03 Colin Hislop Treatment of major adverse cardiac events and acute coronary syndrome in diabetic patients using secretory phospholipase a2 (spla2) inhibitor or spla2 inhibitor combination therapies
US20150224094A1 (en) 2012-09-10 2015-08-13 Ophirex, Inc. Administration of acetylcholinesterase inhibitors to mitigate neurotoxin-induced paralysis and residual neuromuscular blockade
US20140087003A1 (en) * 2012-09-21 2014-03-27 Ignacio Cisneros Method for treating venomous bites and stings
MA40998A (fr) * 2014-11-21 2017-09-26 Ophirex Inc Thérapies contre une envenimation, ainsi que compositions, systèmes et kits pharmaceutiques associés
WO2017152114A1 (en) * 2016-03-04 2017-09-08 Jeffrey Alan Klein Tumescent contravenom drug delivery
EP3448378B1 (en) * 2016-04-29 2024-04-17 Ophirex, Inc. Pla2 and hmg-coa inhibitors for treatment of pathological conditions causing hemolysis, cerebral edema, and acute kidney injury

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999029726A1 (en) * 1997-12-05 1999-06-17 Hsc (Pla) Pty. Ltd. Phospholipase inhibitor

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Cajucarinolide and Isocajucarinolide:Anti-Inflammatory Diterpenes from Croton cajucara;Yoshitatsu Ichihara;《Planta Med》;19921231;第58卷;第549-551页 *
HYMENOPTERA STINGS AND THE ACUTE KIDNEY INJURY;Dongol et al;《EMJ Neph》;20131231;第1卷;第72页 *
Phospholipase A2 inhibitors for the treatment of inflammatory diseases: a patent review (2010 -present);Victoria Magrioti et al;《EXPERT OPINION ON THERAPEUTIC PATENTS》;20130108;第23卷(第3期);第334页 *
Recent Developments with Lipoprotein-Associated Phospholipase A2 Inhibitors;Chauffe et al;《Curr Atheroscler Rep》;20091224;第12卷;第43-47页 *

Also Published As

Publication number Publication date
AU2017257185A1 (en) 2018-11-22
CA3022013A1 (en) 2017-11-02
KR20190005898A (ko) 2019-01-16
US20210220332A1 (en) 2021-07-22
US20250120949A1 (en) 2025-04-17
KR20230049762A (ko) 2023-04-13
BR112018072162A2 (pt) 2019-02-12
MX391165B (es) 2025-03-21
CN116585306B (zh) 2025-06-20
AU2017257185B2 (en) 2023-06-22
IL307232B1 (en) 2025-12-01
IL262620B2 (en) 2024-02-01
CN116585306A (zh) 2023-08-15
EP3448378A4 (en) 2020-04-08
KR102723249B1 (ko) 2024-10-28
CN109562098A (zh) 2019-04-02
MX2018013084A (es) 2019-03-06
IL262620A (en) 2018-12-31
JP7542935B2 (ja) 2024-09-02
MX2022003739A (es) 2022-05-02
EP3448378C0 (en) 2024-04-17
IL262620B1 (en) 2023-10-01
AU2023233187A1 (en) 2023-10-12
JP2019514935A (ja) 2019-06-06
AU2017257185B9 (en) 2023-07-06
JP2022177020A (ja) 2022-11-30
AU2017257185B8 (en) 2023-07-06
EP3448378A1 (en) 2019-03-06
WO2017190141A1 (en) 2017-11-02
US12383531B2 (en) 2025-08-12
EP3448378B1 (en) 2024-04-17
IL307232A (en) 2023-11-01

Similar Documents

Publication Publication Date Title
US20250120949A1 (en) Use of spla2 inhibitors to treat envenomation by snakes and wasps
US12274691B2 (en) Envenomation therapies and related pharmaceutical compositions, systems and kits
CZ20013149A3 (cs) Léčivo proti chronické obstrukční pulmonární chorobě a způsob jeho výroby
US20250120950A1 (en) Use of spla2 inhibitors to treat hymenoptera envenomation, hemolysis, and kidney disease, and to protect blood from osmotic fragility
CA3022013C (en) Secreted pla2 inhibitors for immediate treatment of hymenoptera envenomation
HK40006646A (en) Pla2 inhibitors for immediate treatment of hymenoptera envenomation and other conditions caused by histamine release
HK40006646B (en) Pla2 inhibitors for immediate treatment of hymenoptera envenomation and other conditions caused by histamine release
BR112018072162B1 (pt) Uso de um inibidor de molécula pequena da fosfolipase a2 (pla2)
HK1239573B (zh) 毒液蛰入治疗方法及相关药物组合物、系统和试剂盒
HK1239573A1 (en) Envenomation therapies and related pharmaceutical compositions, systems and kits

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40006646

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant